1
|
Ain QU, Muhammad S, Hai Y, Peiling L. The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours. J OBSTET GYNAECOL 2023; 42:3441-3449. [PMID: 36757337 DOI: 10.1080/01443615.2022.2151352] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Ovarian cancer (OC) is one of the leading causes of gynaecological cancer mortality in women worldwide. If detected at an early stage (I, II), OC has a 90% 5-year survival rate; nevertheless, symptoms are often hidden, leading to late-stage (III, IV) diagnosis and a poor prognosis. The current diagnostic procedures, such as a pelvic exam, transvaginal ultrasound, CA-125 blood tests, serum HE4 tests and multivariate index assays (MIA), are insufficient. Sadly, surgery is frequently required to confirm a positive diagnosis. Therefore, there has been an increased interest in different biomarkers using a non-invasive test as a tool for the earlier diagnosis of OC to resolve the need for precise and non-invasive diagnostic methods. This review article aims to investigate how biomarkers influence early OC detection and to emphasise the role of using a combination of serum biomarkers panel rather than a single biomarker. In addition, this review provides insights into the current serum biomarkers, urine biomarkers and other emerging biomarkers in the early detection of OC for better specificity and sensitivity and to improve the overall survival (OS) rate.
Collapse
Affiliation(s)
- Qurat Ul Ain
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin medical university, Harbin, PR China
| | - Shan Muhammad
- Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China
| | - Yang Hai
- Department of International Education, Harbin Medical University, Harbin, PR China
| | - Li Peiling
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin medical university, Harbin, PR China
| |
Collapse
|
2
|
Zalfa F, Perrone MG, Ferorelli S, Laera L, Pierri CL, Tolomeo A, Dimiccoli V, Perrone G, De Grassi A, Scilimati A. Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma. Cancers (Basel) 2022; 14:cancers14153764. [PMID: 35954427 PMCID: PMC9367275 DOI: 10.3390/cancers14153764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 07/27/2022] [Accepted: 07/28/2022] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Despite ovarian serous adenocarcinoma (OSCA) is a high-incidence type of cancer, limited molecular screening methods are available and the diagnosis mostly occurs at a late stage. The aim of this study is screening the potential of gene expression for identifying OSCA-specific molecular biomarkers for improving diagnosis. A genome-wide survey was performed on high-throughput RNA-sequencing experiments on hundreds ovarian cancer samples and healthy ovarian tissues, providing a number of putative OSCA biomarkers, which were then validated on an independent sample set and using a different RNA-quantification technology. Combinations of gene expression biomarkers were identified, which showed high accuracy in discriminating OSCA tissues from the normal counterpart and from other tumor types. The detected biomarkers can improve the molecular diagnosis of OSCA on tissue samples and are, in principle, translatable to the analysis of liquid biopsies. Abstract Ovarian cancer is the second most prevalent gynecologic malignancy, and ovarian serous cystadenocarcinoma (OSCA) is the most common and lethal subtype of ovarian cancer. Current screening methods have strong limits on early detection, and the majority of OSCA patients relapse. In this work, we developed and cross-validated a method for detecting gene expression biomarkers able to discriminate OSCA tissues from healthy ovarian tissues and other cancer types with high accuracy. A preliminary ranking-based approach was applied, resulting in a panel of 41 over-expressed genes in OSCA. The RNA quantity gene expression of the 41 selected genes was then cross-validated by using NanoString nCounter technology. Moreover, we showed that the RNA quantity of eight genes (ADGRG1, EPCAM, ESRP1, MAL2, MYH14, PRSS8, ST14 and WFDC2) discriminates each OSCA sample from each healthy sample in our data set with sensitivity of 100% and specificity of 100%. For the other three genes (MUC16, PAX8 and SOX17) in combination, their RNA quantity may distinguish OSCA from other 29 tumor types.
Collapse
Affiliation(s)
- Francesca Zalfa
- Predictive Molecular Diagnostic Unit, Pathology Department, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy;
- Microscopic and Ultrastructural Anatomy Unit, CIR, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
| | - Maria Grazia Perrone
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy; (M.G.P.); (S.F.)
| | - Savina Ferorelli
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy; (M.G.P.); (S.F.)
| | - Luna Laera
- Department of Biosciences, Biotechnologies, Biopharmaceutics, University of Bari “Aldo Moro”, 70125 Bari, Italy; (L.L.); (C.L.P.)
| | - Ciro Leonardo Pierri
- Department of Biosciences, Biotechnologies, Biopharmaceutics, University of Bari “Aldo Moro”, 70125 Bari, Italy; (L.L.); (C.L.P.)
| | - Anna Tolomeo
- Department of ITELPHARMA, ITEL Telecomunicazioni S.R.L., 70037 Ruvo di Puglia, Italy; (A.T.); (V.D.)
| | - Vincenzo Dimiccoli
- Department of ITELPHARMA, ITEL Telecomunicazioni S.R.L., 70037 Ruvo di Puglia, Italy; (A.T.); (V.D.)
| | - Giuseppe Perrone
- Pathology Department, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy;
- Pathology Research Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
| | - Anna De Grassi
- Department of Biosciences, Biotechnologies, Biopharmaceutics, University of Bari “Aldo Moro”, 70125 Bari, Italy; (L.L.); (C.L.P.)
- Correspondence: (A.D.G.); (A.S.)
| | - Antonio Scilimati
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy; (M.G.P.); (S.F.)
- Correspondence: (A.D.G.); (A.S.)
| |
Collapse
|
3
|
Yung MMH, Siu MKY, Ngan HYS, Chan DW, Chan KKL. Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers. Int J Mol Sci 2022; 23:ijms23126857. [PMID: 35743298 PMCID: PMC9224484 DOI: 10.3390/ijms23126857] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 06/06/2022] [Accepted: 06/17/2022] [Indexed: 02/06/2023] Open
Abstract
Ovarian cancer is one of the most lethal gynecological malignancies worldwide, and chemoresistance is a critical obstacle in the clinical management of the disease. Recent studies have suggested that exploiting cancer cell metabolism by applying AMP-activated protein kinase (AMPK)-activating agents and distinctive adjuvant targeted therapies can be a plausible alternative approach in cancer treatment. Therefore, the perspectives about the combination of AMPK activators together with VEGF/PD-1 blockade as a dual-targeted therapy against ovarian cancer were discussed herein. Additionally, ferroptosis, a non-apoptotic regulated cell death triggered by the availability of redox-active iron, have been proposed to be governed by multiple layers of metabolic signalings and can be synergized with immunotherapies. To this end, ferroptosis initiating therapies (FITs) and metabolic rewiring and immunotherapeutic approaches may have substantial clinical potential in combating ovarian cancer development and progression. It is hoped that the viewpoints deliberated in this review would accelerate the translation of remedial concepts into clinical trials and improve the effectiveness of ovarian cancer treatment.
Collapse
Affiliation(s)
- Mingo M. H. Yung
- Department of Obstetrics & Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; (M.M.H.Y.); (M.K.Y.S.); (H.Y.S.N.)
| | - Michelle K. Y. Siu
- Department of Obstetrics & Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; (M.M.H.Y.); (M.K.Y.S.); (H.Y.S.N.)
| | - Hextan Y. S. Ngan
- Department of Obstetrics & Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; (M.M.H.Y.); (M.K.Y.S.); (H.Y.S.N.)
| | - David W. Chan
- Department of Obstetrics & Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; (M.M.H.Y.); (M.K.Y.S.); (H.Y.S.N.)
- School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
- Correspondence: or (D.W.C.); (K.K.L.C.); Tel.: +852-3917-9367 or +852-3943-6053 (D.W.C.); +852-2255-4260 (K.K.L.C.); Fax: +852-2816-1947 or +852-2603-5123 (D.W.C.); +852-2255-0947 (K.K.L.C.)
| | - Karen K. L. Chan
- Department of Obstetrics & Gynaecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; (M.M.H.Y.); (M.K.Y.S.); (H.Y.S.N.)
- Correspondence: or (D.W.C.); (K.K.L.C.); Tel.: +852-3917-9367 or +852-3943-6053 (D.W.C.); +852-2255-4260 (K.K.L.C.); Fax: +852-2816-1947 or +852-2603-5123 (D.W.C.); +852-2255-0947 (K.K.L.C.)
| |
Collapse
|
4
|
Chen Z, Li B, Liu J, Li H, Li C, Xuan X, Li M. A label-free electrochemical immunosensor based on a gold-vertical graphene/TiO 2 nanotube electrode for CA125 detection in oxidation/reduction dual channels. Mikrochim Acta 2022; 189:257. [PMID: 35701556 DOI: 10.1007/s00604-022-05332-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 05/09/2022] [Indexed: 02/07/2023]
Abstract
A label-free immunosensor was constructed in oxidation and reduction dual channel mode for the trace detection of cancer antigen 125 (CA125) in serum. The gold-vertical graphene/titanium dioxide (Au-VG/TiO2) electrode was used as the signal-amplification platform, and cytosine and dopamine were used as probes in the oxidation and reduction channels, respectively. VG nanosheets were synthesized on a TiO2 nanotube array via chemical vapor deposition (CVD), and Au nanoparticles were deeply embedded on the surface and in the root of the VG nanosheets via electrodeposition. The CA125 antibody was then directly immobilized onto the electrode surface, benefitting from its natural affinity for Au nanoparticles. In the oxidation and reduction channels the CA125 antibody-Au-VG/TiO2 immune electrode had the same response concentration range (0.01-1000 mU∙mL-1) for the determination of the CA125 antigen. However, the oxidation channel had a higher sensitivity (14.82 μA•(log(mU•mL-1))-1 at a working potential of ~ 1.25 V vs. SCE), lower detection limit (0.0001 mU∙mL-1), higher stability, and lower performance deviation than the reduction channel. This immunosensor was successfully used for CA125 detection in human serum. The recoveries of spiked serum samples ranged from 99.8 ± 0.5 to 100 ± 0.4%. The study on the difference in the sensing performance between oxidation and reduction channels provides a preliminary experimental reference for exploring dual-channel synchronous detection immunosensors and verifying the accuracy of the assay based on dual-channel data, which will promote the development of reliable electrochemical immunosensor technology.
Collapse
Affiliation(s)
- Zehua Chen
- Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin Key Laboratory of Drug Targeting and Bioimaging, School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China
| | - Bingbing Li
- Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin Key Laboratory of Drug Targeting and Bioimaging, School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China
| | - Jinbiao Liu
- Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin Key Laboratory of Drug Targeting and Bioimaging, School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China.
| | - Hongji Li
- Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin Key Laboratory of Drug Targeting and Bioimaging, School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China.
| | - Cuiping Li
- Tianjin Key Laboratory of Film Electronic and Communication Devices, Engineering Research Center of Optoelectronic Devices & Communication Technology (Ministry of Education), School of Integrated Circuit Science and Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China
| | - Xiuwei Xuan
- Tianjin Key Laboratory of Film Electronic and Communication Devices, Engineering Research Center of Optoelectronic Devices & Communication Technology (Ministry of Education), School of Integrated Circuit Science and Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China
| | - Mingji Li
- Tianjin Key Laboratory of Film Electronic and Communication Devices, Engineering Research Center of Optoelectronic Devices & Communication Technology (Ministry of Education), School of Integrated Circuit Science and Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China.
| |
Collapse
|
5
|
Wu M, Liu S, Qi F, Qiu R, Feng J, Ren X, Rong S, Ma H, Chang D, Pan H. A label-free electrochemical immunosensor for CA125 detection based on CMK-3(Au/Fc@MgAl-LDH)n multilayer nanocomposites modification. Talanta 2022; 241:123254. [DOI: 10.1016/j.talanta.2022.123254] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 01/13/2022] [Accepted: 01/20/2022] [Indexed: 01/31/2023]
|
6
|
rGO based immunosensor amplified using MWCNT and CNF nanocomposite as analytical tool for CA125 detection. Anal Biochem 2021; 634:114393. [PMID: 34597616 DOI: 10.1016/j.ab.2021.114393] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 09/04/2021] [Accepted: 09/25/2021] [Indexed: 11/24/2022]
Abstract
The electrochemical performance of dual layer immunosensor has been studied by employing reduced Graphene oxide (rGO) and its nanocomposites with Carbon Nanofibers (CNFs) and Carbon Nanotubes (CNTs) as supporting matrix for the detection of CA125. The immunosensor determination was based on the formation of antibody - antigen immunocomplex, a decrement in the current response was observed in accordance with the concentration of antigen. Better performance exhibited by rGO/CNF in terms of linearity (99%) and sensitivity 0.65 μA (μg mL-1)-1 can be attributed to its conductivity and surface area. The nanocomposite are employed in the detection of CA125 with linear working range of 10-32 × 10-4 μg mL-1, the limit of detection is found to be 0.28 pg mL-1 rGO nanocomposite with CNT (rGO/CNT) is studied as transducer material. rGO/CNT exhibited better linearity when compared to rGO due to its good conductivity. Thus, graphene nanocomposite transducer materials have vital application in detection of oncomarkers.
Collapse
|
7
|
Kogej K, Božič D, Kobal B, Herzog M, Černe K. Application of Dynamic and Static Light Scattering for Size and Shape Characterization of Small Extracellular Nanoparticles in Plasma and Ascites of Ovarian Cancer Patients. Int J Mol Sci 2021; 22:ijms222312946. [PMID: 34884751 PMCID: PMC8657631 DOI: 10.3390/ijms222312946] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Accepted: 11/23/2021] [Indexed: 12/14/2022] Open
Abstract
In parallel to medical treatment of ovarian cancer, methods for the early detection of cancer tumors are being sought. In this contribution, the use of non-invasive static (SLS) and dynamic light scattering (DLS) for the characterization of extracellular nanoparticles (ENPs) in body fluids of advanced serous ovarian cancer (OC) and benign gynecological pathology (BP) patients is demonstrated and critically evaluated. Samples of plasma and ascites (OC patients) or plasma, peritoneal fluid, and peritoneal washing (BP patients) were analyzed. The hydrodynamic radius (Rh) and the radius of gyration (Rg) of ENPs were calculated from the angular dependency of LS intensity for two ENP subpopulations. Rh and Rg of the predominant ENP population of OC patients were in the range 20–30 nm (diameter 40–60 nm). In thawed samples, larger particles (Rh mostly above 100 nm) were detected as well. The shape parameter ρ of both particle populations was around 1, which is typical for spherical particles with mass concentrated on the rim, as in vesicles. The Rh and Rg of ENPs in BP patients were larger than in OC patients, with ρ ≈ 1.1–2, implying a more elongated/distorted shape. These results show that SLS and DLS are promising methods for the analysis of morphological features of ENPs and have the potential to discriminate between OC and BP patients. However, further development of the methodology is required.
Collapse
Affiliation(s)
- Ksenija Kogej
- Faculty of Chemistry and Chemical Technology, Department of Chemistry and Biochemistry, University of Ljubljana, SI-1000 Ljubljana, Slovenia;
- Correspondence:
| | - Darja Božič
- Faculty of Chemistry and Chemical Technology, Department of Chemistry and Biochemistry, University of Ljubljana, SI-1000 Ljubljana, Slovenia;
- Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Borut Kobal
- Division of Gynecology and Obstetrics, Department of Gynecology, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia; (B.K.); (M.H.)
- Faculty of Medicine, Department of Gynecology and Obstetrics, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Maruša Herzog
- Division of Gynecology and Obstetrics, Department of Gynecology, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia; (B.K.); (M.H.)
- Faculty of Medicine, Department of Gynecology and Obstetrics, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Katarina Černe
- Faculty of Medicine, Department of Pharmacology and Experimental Toxicology, University of Ljubljana, SI-1000 Ljubljana, Slovenia;
| |
Collapse
|
8
|
Capriotti A, Piovesana S, Zenezini Chiozzi R, Montone CM, Bossi AM, Laganà A. Does the protein corona take over the selectivity of molecularly imprinted nanoparticles? The biological challenges to recognition. J Proteomics 2020; 219:103736. [PMID: 32198073 DOI: 10.1016/j.jprot.2020.103736] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 02/15/2020] [Accepted: 03/10/2020] [Indexed: 12/19/2022]
Abstract
"Plastic antibodies" are nano-sized biomimetics prepared by the molecular imprinting technology, which have the robustness of polymers, but specificity and selectivity alike natural receptors making them ideal for analytical uses. The current challenge is to translate plastic antibodies to in vivo applications for diagnosis, drug delivery, theranostic, therefore it is crucial to evaluate the effect of the biological sample complexity on the selectivity and the formation of protein corona (PCs), which ultimately dictate the fate of circulating nanoparticles. A set (n = 4) of plastic antibodies (nanoMIPs) against different proteins was prepared. Quantitative (iBAC) shotgun proteomics permitted to define the PC composition of nanoMIPs in human plasma, the relative protein abundances, the correlation between PC and the plasma dilution. NanoMIPs showed >200 proteins PC, while ~150 proteins were found on controls, suggesting the imprinting process influences the nanoparticle's structure hence the protein uptake. NanoMIPs and controls shared the 44% of the PC, but PC iBAQ values on nanoMIPs were 10-100 times higher than controls, suggesting PC/nanoMIPs interactions were far stronger than PC/non imprinted particles. PCs were richer in small proteins and in immunoglobulins, indicating a defensive response, while the selectivity was negatively challenged in the crowded plasma sample. SIGNIFICANCE: The formation and the composition of the protein corona (PC) is key to decide the fate of nanoparticles when in vivo, therefore there is the strong need to study the composition of the PC. To enable and to support the translation of the use of plastic antibodies (nanoMIPs), prepared by means of the molecular imprinting technique, to the clinical practice and to in vivo uses, the present work evaluates the effects of the complexity of the biological sample (plasma) on nanoMIPs composed of highly crosslinked polyacrylamide and acrylamide derivatives. Proteomic study offers an in depth insight of the protein corona formed in plasma on nanoMIPs. A set of nanoMIPs synthesized and raised to recognize either small or large proteins was tested. The selection abilities of the nanoMIPs when placed in plasma at different dilutions was studied. Quantitative shotgun proteomics allowed to define the composition of the formed protein corona (PC) enabling to detail the protein compositions, the relative abundances, its correlation to the biological sample composition and the correlation between PC and nanoMIP's imprinted template. In plasma, all the nanoMIPs gained a PC composed of more than 200 proteins. Type of protein recruited for the corona, molecular weight and abundance in the PC were studied. The PC on the nanoMIPs appeared to be driven by the protein composition of the plasma, while the template protein, towards which a nanoMIP was imprinted and that was proven to have high affinity for, did not influence the PC.
Collapse
Affiliation(s)
- Annalaura Capriotti
- University of Rome "La Sapienza", Department of Chemistry, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Susy Piovesana
- University of Rome "La Sapienza", Department of Chemistry, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Carmela Maria Montone
- University of Rome "La Sapienza", Department of Chemistry, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Alessandra Maria Bossi
- University of Verona, Department of Biotechnology, Strada Le Grazie 15, 37134 Verona, Italy.
| | - Aldo Laganà
- University of Rome "La Sapienza", Department of Chemistry, Piazzale Aldo Moro 5, 00185 Rome, Italy
| |
Collapse
|
9
|
Aziz NB, Mahmudunnabi RG, Umer M, Sharma S, Rashid MA, Alhamhoom Y, Shim YB, Salomon C, Shiddiky MJA. MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors. Analyst 2020; 145:2038-2057. [DOI: 10.1039/c9an02263e] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Ovarian cancer is the most aggressive of all gynaecological malignancies and is the leading cause of cancer-associated mortality worldwide.
Collapse
Affiliation(s)
- Nahian Binte Aziz
- School of Environment and Science
- Griffith University
- Nathan Campus
- Australia
- School of Chemistry & Molecular Biosciences
| | - Rabbee G. Mahmudunnabi
- Department of Molecular Science Technology and Institute of BioPhysio Sensor Technology (IBST)
- Pusan National University
- Busan 46241
- Republic of Korea
| | - Muhammad Umer
- Queensland Micro and nanotechnology Centre
- Griffith University
- Nathan Campus
- Australia
| | - Shayna Sharma
- Exosome Biology Laboratory
- Centre for Clinical Diagnostics
- University of Queensland Centre for Clinical Research
- Royal Brisbane and Women's Hospital
- The University of Queensland
| | - Md Abdur Rashid
- Department of Pharmaceutics
- College of Pharmacy
- King Khalid University
- Abha
- Kingdom of Saudi Arabia
| | - Yahya Alhamhoom
- Department of Pharmaceutics
- College of Pharmacy
- King Khalid University
- Abha
- Kingdom of Saudi Arabia
| | - Yoon-Bo Shim
- Department of Chemistry and Institute of BioPhysio Sensor Technology (IBST)
- Pusan National University
- Busan 46241
- Republic of Korea
| | - Carlos Salomon
- Exosome Biology Laboratory
- Centre for Clinical Diagnostics
- University of Queensland Centre for Clinical Research
- Royal Brisbane and Women's Hospital
- The University of Queensland
| | - Muhammad J. A. Shiddiky
- School of Environment and Science
- Griffith University
- Nathan Campus
- Australia
- Queensland Micro and nanotechnology Centre
| |
Collapse
|
10
|
Mathis J, Jellouli MA, Sabiani L, Fest J, Blache G, Mathevet P. Ovarian cancer screening in the general population. Horm Mol Biol Clin Investig 2019; 41:hmbci-2019-0038. [PMID: 31693493 DOI: 10.1515/hmbci-2019-0038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 10/01/2019] [Indexed: 12/13/2022]
Abstract
Background Ovarian carcinoma is a poor prognosis cancer mainly due to its late diagnosis. Its incidence is relatively low but mortality is high. The symptomatology is only slightly specific, which complicates diagnostic management. It would therefore be interesting to be able to establish a diagnosis as early as possible in order to improve the prognosis of patients suffering from ovarian cancer. Materials and methods Currently, the combination of an ultrasound examination with a cancer antigen (CA)-125 assay is the most effective diagnostic technique, but not already admitted as a screening method. Therefore, we realized an exhaustive analysis of the most important studies in the last 15 years, in order to find new approaches in ovarian cancer screening. Results The age for initiating screening and its frequency are issues that are not fully resolved. The false positives and morbidity that result from screening are currently notable limitations. Conclusions The latest data do not support effective screening in the general population.
Collapse
Affiliation(s)
- Jérôme Mathis
- Centre Hospitalier Universitaire Vaudois, Department of Gynecology, Lausanne, Switzerland.,Centre Hospitalier Bienne, Department of Gynecology, Service de Gynécologie et Obstétrique, Chante-Merle 84, 2501 Bienne, Switzerland, Phone: 0041 32 324 17 13
| | | | - Laura Sabiani
- Institut Paoli-Calmettes, Department of Surgical Oncology, Marseille, France
| | - Joy Fest
- Centre Hospitalier Bienne, Department of Gynecology, Bienne, Switzerland
| | - Guillaume Blache
- Institut Paoli-Calmettes, Department of Surgical Oncology, Marseille, France
| | - Patrice Mathevet
- Centre Hospitalier Universitaire Vaudois, Department of Gynecology, Lausanne, Switzerland
| |
Collapse
|
11
|
Bing Z, Yao Y, Xiong J, Tian J, Guo X, Li X, Zhang J, Shi X, Zhang Y, Yang K. Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets. Front Genet 2019; 10:931. [PMID: 31681404 PMCID: PMC6798149 DOI: 10.3389/fgene.2019.00931] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Accepted: 09/05/2019] [Indexed: 12/31/2022] Open
Abstract
Different analytical methods or models can often find completely different prognostic biomarkers for the same cancer. In the study of prognostic molecular biomarkers of ovarian cancer (OvCa), different studies have reported a variety of prognostic gene signatures. In the current study, based on geometric concepts, the linearity-clustering phase diagram with integrated P-value (LCP) method was used to comprehensively consider three indicators that are commonly employed to estimate the quality of a prognostic gene signature model. The three indicators, namely, concordance index, area under the curve, and level of the hazard ratio were determined via calculation of the prognostic index of various gene signatures from different datasets. As evaluation objects, we selected 13 gene signature models (Cox regression model) and 16 OvCa genomic datasets (including gene expression information and follow-up data) from published studies. The results of LCP showed that three models were universal and better than other models. In addition, combining the three models into one model showed the best performance in all datasets by LCP calculation. The combination gene signature model provides a more reliable model and could be validated in various datasets of OvCa. Thus, our method and findings can provide more accurate prognostic biomarkers and effective reference for the precise clinical treatment of OvCa.
Collapse
Affiliation(s)
- Zhitong Bing
- Evidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, China.,Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.,Department of Computational Physics, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
| | - Yuxiang Yao
- School of Physical Science and Technology, Lanzhou University, Lanzhou, China
| | - Jie Xiong
- Department of Applied Mathematics, Changsha University, Changsha, China
| | - Jinhui Tian
- Evidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, China.,Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China
| | - Xiangqian Guo
- Medical Bioinformatics Institute, School of Basic Medicine, Henan University, Henan, China
| | - Xiuxia Li
- Evidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, China.,Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.,School of Public Health, Lanzhou University, Lanzhou, China
| | - Jingyun Zhang
- Evidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, China.,Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China
| | - Xiue Shi
- Institute for Evidence Based Rehabilitation Medicine of Gansu Province, Lanzhou, China
| | - Yanying Zhang
- Department of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China
| | - Kehu Yang
- Evidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, China.,Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.,Institute for Evidence Based Rehabilitation Medicine of Gansu Province, Lanzhou, China.,Department of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China
| |
Collapse
|
12
|
Singh A, Gupta S, Sachan M. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol 2019; 7:182. [PMID: 31608277 PMCID: PMC6761254 DOI: 10.3389/fcell.2019.00182] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 08/19/2019] [Indexed: 12/15/2022] Open
Abstract
Ovarian cancer (OC) causes significant morbidity and mortality as neither detection nor screening of OC is currently feasible at an early stage. Difficulty to promptly diagnose OC in its early stage remains challenging due to non-specific symptoms in the early-stage of the disease, their presentation at an advanced stage and poor survival. Therefore, improved detection methods are urgently needed. In this article, we summarize the potential clinical utility of epigenetic signatures like DNA methylation, histone modifications, and microRNA dysregulation, which play important role in ovarian carcinogenesis and discuss its application in development of diagnostic, prognostic, and predictive biomarkers. Molecular characterization of epigenetic modification (methylation) in circulating cell free tumor DNA in body fluids offers novel, non-invasive approach for identification of potential promising cancer biomarkers, which can be performed at multiple time points and probably better reflects the prevailing molecular profile of cancer. Current status of epigenetic research in diagnosis of early OC and its management are discussed here with main focus on potential diagnostic biomarkers in tissue and body fluids. Rapid and point of care diagnostic applications of DNA methylation in liquid biopsy has been precluded as a result of cumbersome sample preparation with complicated conventional methods of isolation. New technologies which allow rapid identification of methylation signatures directly from blood will facilitate sample-to answer solutions thereby enabling next-generation point of care molecular diagnostics. To date, not a single epigenetic biomarker which could accurately detect ovarian cancer at an early stage in either tissue or body fluid has been reported. Taken together, the methodological drawbacks, heterogeneity associated with ovarian cancer and non-validation of the clinical utility of reported potential biomarkers in larger ovarian cancer populations has impeded the transition of epigenetic biomarkers from lab to clinical settings. Until addressed, clinical implementation as a diagnostic measure is a far way to go.
Collapse
Affiliation(s)
- Alka Singh
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| | - Sameer Gupta
- Department of Surgical Oncology, King George Medical University, Lucknow, India
| | - Manisha Sachan
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| |
Collapse
|
13
|
Fan Y, Shi S, Ma J, Guo Y. A paper-based electrochemical immunosensor with reduced graphene oxide/thionine/gold nanoparticles nanocomposites modification for the detection of cancer antigen 125. Biosens Bioelectron 2019; 135:1-7. [DOI: 10.1016/j.bios.2019.03.063] [Citation(s) in RCA: 77] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 03/28/2019] [Accepted: 03/31/2019] [Indexed: 12/20/2022]
|
14
|
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2019; 41:716-721. [PMID: 27906723 PMCID: PMC5449266 DOI: 10.1097/coc.0000000000000353] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
PURPOSE One-year monitoring of patients receiving intraperitoneal (IP) Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of Pb-TCMC-trastuzumab, delivered <4 h after 4 mg/kg IV trastuzumab. Seven tumor markers were studied for correlation with outcome. RESULTS Six dose levels (7.4, 9.6, 12.6, 16.3, 21.1, 27.4 MBq/m) were well tolerated with early possibly agent-related adverse events being mild, transient, and not dose dependent. These included asymptomatic, abnormal laboratory values. No late renal, liver, cardiac, or other toxicity was noted up to 1 year. There were no clinical signs or symptoms of an immune response to Pb-TCMC-trastuzumab, and assays to detect an immune response to this conjugate were negative for all tested. Tumor marker studies in ovarian cancer patients showed a trend of decreasing Cancer antigen 72-4 (CA 72-4) aka tumor-associated glycoprotein 72 (TAG-72) and tumor growth with increasing administered radioactivity. Other tumor markers, including carbohydrate antigen (CA125), human epididymis protein 4 (HE-4), serum amyloid A (SAA), mesothelin, interleukin-6 (IL-6), and carcinoembryonic antigen (CEA) did not correlate with imaging outcome. CONCLUSIONS IP Pb-TCMC-trastuzumab up to 27 MBq/m seems safe for patients with peritoneal carcinomatosis who have failed standard therapies. Serum TAG-72 levels better correlated to imaging changes in ovarian cancer patients than the more common tumor marker, CA125.
Collapse
|
15
|
Grayson K, Gregory E, Khan G, Guinn BA. Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet? BIOMARKERS IN CANCER 2019; 11:1179299X19830977. [PMID: 30833816 PMCID: PMC6393943 DOI: 10.1177/1179299x19830977] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 01/24/2019] [Indexed: 12/20/2022]
Abstract
Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Current diagnostic methods are invasive and consist of a pelvic examination, transvaginal ultrasonography, and blood tests to detect cancer antigen 125 (CA125). Unfortunately, surgery is often still required to make a positive diagnosis. To address the need for accurate, specific, and non-invasive diagnostic methods, there has been an increased interest in biomarkers identified through non-invasive tests as tools for the earlier diagnosis of ovarian cancer. Although most studies have focused on the identification of biomarkers in blood, the ease of availability of urine and the high patient compliance rates suggest that it could provide a promising resource for the screening of patients for ovarian cancer.
Collapse
Affiliation(s)
- Kelly Grayson
- Department of Biomedical Sciences, University of Hull, Hull, UK
| | - Ebony Gregory
- Department of Biomedical Sciences, University of Hull, Hull, UK
| | - Ghazala Khan
- Department of Biomedical Sciences, University of Hull, Hull, UK
| | | |
Collapse
|
16
|
Moradi MT, Khazaei M, Khazaei M. The effect of catalase C262T gene polymorphism in susceptibility to ovarian cancer in Kermanshah province, Western Iran. J OBSTET GYNAECOL 2018; 38:562-566. [PMID: 29421935 DOI: 10.1080/01443615.2017.1381672] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Ovarian cancer has a heterogeneous biology and behaviour. Oxidative stress can initiate chronic inflammation, which can sequentially facilitate chronic diseases, including cancer. Oxidative stress may arise when there is extra reactive oxygen species (ROS) production and/or inadequate defence mechanisms. There are some antioxidant defences that can fight against oxidative damage, including catalase (CAT) enzyme. We sought to evaluate the association of CAT C262T gene polymorphism with increased risk of ovarian cancer. A total of 74 paraffin-embedded ovarian cancer blocks were taken from the archive of Imam-Reza Hospital, Kermanshah University of Medical Sciences, between 2010 and 2014. Also, 153 blood samples were harvested from healthy volunteers. For genotyping of CAT C262T, we designed allele-specific polymerase chain reaction (AS-PCR). 'T' allele of CAT C262T showed a protective effect against the risk of ovarian cancer [OR = 0.4 (95% CI 0.25-0.6), p value <.001]. Calculating adjusted odds ratio showed the distribution of alleles and genotypes was not affected by age. The present study reported a significant association between the distribution of CAT C262T gene polymorphism and ovarian cancer for the first time in a sample of the Iranian population. Impact Statement What is already known on this subject: Ovarian cancer has a heterogeneous biology and behaviour at the clinical, cellular and molecular aspects. Ovulation releases follicular fluid containing reactive oxygen species which is related to changes in the microenvironment, such as inflammation, that could be a factor in early ovarian carcinogenesis. There are some antioxidant defences that can protect cells against oxidative damage, including catalase (CAT). Different studies investigated the relationships between CAT C262T polymorphism and several diseases. Belotte et al. ( 2015 ), for the first time, indicated no significant association between CAT C262T and the risk of ovarian cancer, while they showed this SNP is associated with poor survival and therefore may serve as a prognostic factor for ovarian cancer. What the results of this study add: In the present study, 'T' allele of CAT C262T showed a protective effect against the risk of ovarian cancer. Calculating adjusted odds ratio showed that the distribution of alleles and genotypes is not affected by age. What the implications are of these findings for clinical practice and/or further research: Pair-wise genetic analyses using SNPSTATS software showed that this genotyping was more compatible with recessive models, i.e. two copies of the associated variant are required to increase the risk of ovarian cancer. Further research about other antioxidant genes in a larger population is needed to predict the risk of ovarian cancer and survival rate of patients.
Collapse
Affiliation(s)
- Mohammad-Taher Moradi
- a Fertility and Infertility Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran
| | - Mansour Khazaei
- a Fertility and Infertility Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran
| | - Mozafar Khazaei
- a Fertility and Infertility Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran
| |
Collapse
|
17
|
Cell Cycle Model System for Advancing Cancer Biomarker Research. Sci Rep 2017; 7:17989. [PMID: 29269772 PMCID: PMC5740075 DOI: 10.1038/s41598-017-17845-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Accepted: 11/27/2017] [Indexed: 01/14/2023] Open
Abstract
Progress in understanding the complexity of a devastating disease such as cancer has underscored the need for developing comprehensive panels of molecular markers for early disease detection and precision medicine applications. The present study was conducted to assess whether a cohesive biological context can be assigned to protein markers derived from public data mining, and whether mass spectrometry can be utilized to screen for the co-expression of functionally related biomarkers to be recommended for further exploration in clinical context. Cell cycle arrest/release experiments of MCF7/SKBR3 breast cancer and MCF10 non-tumorigenic cells were used as a surrogate to support the production of proteins relevant to aberrant cell proliferation. Information downloaded from the scientific public domain was queried with bioinformatics tools to generate an initial list of 1038 cancer-associated proteins. Mass spectrometric analysis of cell extracts identified 352 proteins that could be matched to the public list. Differential expression, enrichment, and protein-protein interaction analysis of the proteomic data revealed several functionally-related clusters of relevance to cancer. The results demonstrate that public data derived from independent experiments can be used to inform biological research and support the development of molecular assays for probing the characteristics of a disease.
Collapse
|
18
|
Yeganeh PN, Richardson C, Bahrani-Mostafavi Z, Tait DL, Mostafavi MT. Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues. Genes Cancer 2017; 8:784-798. [PMID: 29321820 PMCID: PMC5755724 DOI: 10.18632/genesandcancer.164] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 12/01/2017] [Indexed: 01/14/2023] Open
Abstract
Screening methods of High-Grade Serous Ovarian Cancer (HGSOC) lack specificity and sensitivity, partly due to benign tumors producing false-positive findings. We utilized a differential expression analysis pipeline on malignant tumor (MT) and normal epithelial (NE) samples, and also filtered the results to discriminate between MT and benign tumor (BT). We report that a panel of 26 dysregulated genes stratifies MT from both BT and NE. We further validated our findings by utilizing unsupervised clustering methods on two independent datasets. We show that the 26-genes panel completely distinguishes HGSOC from NE, and produces a more accurate classification between HGSOC and BT. Pathway analysis reveals that AKT3 is of particular significance, because of its high fold change and appearance in the majority of the dysregulated pathways. mRNA patterns of AKT3 suggest essential connections with tumor growth and metastasis, as well as a strong biomarker potential when used with 3 other genes (PTTG1, MND1, CENPF). Our results show that dysregulation of the 26-mRNA signature panel provides an evidence of malignancy and contribute to the design of a high specificity biomarker panel for detection of HGSOC, potentially in an early more curable stage.
Collapse
Affiliation(s)
- Pourya Naderi Yeganeh
- College of Computing and Informatics, University of North Carolina at Charlotte, Charlotte, NC, USA
| | - Christine Richardson
- Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
| | - Zahra Bahrani-Mostafavi
- College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, USA
| | - David L. Tait
- Division of Gynecological Oncology and Obstetrics, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA
| | - M. Taghi Mostafavi
- College of Computing and Informatics, University of North Carolina at Charlotte, Charlotte, NC, USA
| |
Collapse
|
19
|
Cenci L, Bertolla M, Anesi A, Ambrosi E, Guella G, Bossi AM. Micro- versus nano-sized molecularly imprinted polymers in MALDI-TOF mass spectrometry analysis of peptides. Anal Bioanal Chem 2017; 409:6253-6261. [DOI: 10.1007/s00216-017-0569-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Revised: 07/12/2017] [Accepted: 08/04/2017] [Indexed: 11/24/2022]
|
20
|
Turan T, Torun M, Atalay F, Gönenç A. Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers. Turk J Pharm Sci 2017; 14:141-147. [PMID: 32454605 DOI: 10.4274/tjps.81994] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Accepted: 04/13/2017] [Indexed: 12/01/2022]
Abstract
Objectives Extracellular matrix components, including vitronectin (VN), soluble epithelial-cadherin (sE-cadherin) and transforming growth factor-beta 1 (TGF-β1), play a key role in the invasion and metastasis of cancer. The objective of the study was to determine the clinical significance of serum levels of these molecules in patients with endometrial and ovarian cancers. Materials and Methods Serum levels of VN, sE-cadherin and TGF-β1 in patients with endometrial (n=28) and ovarian cancers (n=40) and healthy controls (n=41) were measured by ELISA using commercial kits. Results A significant difference was found in VN, sE-cadherin and TGF-β1 levels between patients and healthy controls (p<0.01, p<0.01 and p<0.05, respectively). Serum VN and sE-cadherin levels were decreased significantly in both endometrial and ovarian cancer patients compared to controls (p<0.01, p<0.01, respectively). Conversely, TGF-β1 levels were increased significantly in patients with ovarian cancer as compared to controls (p<0.01). There was no significant difference between healthy controls and endometrial cancer patients. Conclusion In conclusion, our study reveals that serum VN, sE-cadherin and TGF-β1 levels can be candidate targets for providing new diagnostic procedures in endometrial and ovarian cancers.
Collapse
Affiliation(s)
- Taylan Turan
- Gazi University, Faculty Of Pharmacy, Department Of Biochemistry, Ankara, Turkey
| | - Meral Torun
- Gazi University, Faculty Of Pharmacy, Department Of Biochemistry, Ankara, Turkey
| | - Funda Atalay
- Ankara Oncology Training And Research Hospital, Clinic Of Obstetrics And Gynecology, Ankara, Turkey
| | - Aymelek Gönenç
- Gazi University, Faculty Of Pharmacy, Department Of Biochemistry, Ankara, Turkey
| |
Collapse
|
21
|
赖 爱, 谢 斌. BCAT1促进肿瘤发生发展的研究进展. Shijie Huaren Xiaohua Zazhi 2017; 25:1536-1542. [DOI: 10.11569/wcjd.v25.i17.1536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
支链氨基酸转移酶1(branched-chain amino acid transaminase 1, BCAT1)是催化支链氨基酸代谢的关键酶. 国内外研究已证实BCAT1在多种恶性肿瘤中呈现高表达, 并提示与肿瘤细胞增殖、转移及侵袭密切相关. 本文拟就BCAT1的理化性质、生物学功能及其与肿瘤发生、发展的相关研究进行简要综述, 为进一步研究BCAT1与恶性肿瘤的关系提供线索.
Collapse
|
22
|
|
23
|
Pierredon S, Ribaux P, Tille JC, Petignat P, Cohen M. Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. Oncol Lett 2017; 13:4965-4973. [PMID: 28599499 DOI: 10.3892/ol.2017.6096] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 12/16/2016] [Indexed: 01/19/2023] Open
Abstract
Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription-quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.
Collapse
Affiliation(s)
- Sandra Pierredon
- Department of Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland
| | - Pascale Ribaux
- Department of Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland
| | | | - Patrick Petignat
- Department of Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland
| | - Marie Cohen
- Department of Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland
| |
Collapse
|
24
|
Taherian-Esfahani Z, Abedin-Do A, Nikpayam E, Tasharofi B, Ghahghaei Nezamabadi A, Ghafouri-Fard S. Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers. IRANIAN JOURNAL OF CANCER PREVENTION 2016. [DOI: 10.17795/ijcp-4993] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
25
|
Cirillo PM, Wang ET, Cedars MI, Chen LM, Cohn BA. Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies. Int J Cancer 2016; 139:1009-17. [PMID: 27082375 PMCID: PMC6917033 DOI: 10.1002/ijc.30144] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 02/12/2016] [Accepted: 03/18/2016] [Indexed: 01/07/2023]
Abstract
We tested the hypothesis that irregular menstruation predicts lower risk for ovarian cancer, possibly due to less frequent ovulation. We conducted a 50-year prospective study of 15,528 mothers in the Child Health and Development Studies cohort recruited from the Kaiser Foundation Health Plan from 1959 to 1966. Irregular menstruation was classified via medical record and self-report at age 26. We identified 116 cases and 84 deaths due to ovarian cancer through 2011 via linkage to the California Cancer Registry and Vital Statistics. Contrary to expectation, women with irregular menstrual cycles had a higher risk of ovarian cancer incidence and mortality over the 50-year follow-up. Associations increased with age (p <0.05). We observed a 2-fold increased incidence and mortality by age 70 (95% confidence interval [CI] = 1.1, 3.4) rising to a 3-fold increase by age 77 (95% CI = 1.5, 6.7 for incidence; 95% CI = 1.4, 5.9 for mortality). We also found a 3-fold higher risk of mortality for high-grade serous tumors (95% CI = 1.3, 7.6) that did not vary by age. This is the first prospective study to show an association between irregular menstruation and ovarian cancer-we unexpectedly found higher risk for women with irregular cycles. These women are easy to identify and many may have polycystic ovarian syndrome. Classifying high-risk phenotypes such as irregular menstruation creates opportunities to find novel early biomarkers, refine clinical screening protocols and potentially develop new risk reduction strategies. These efforts can lead to earlier detection and better survival for ovarian cancer.
Collapse
Affiliation(s)
- Piera M. Cirillo
- Child Health and Development Studies of the Public Health Institute, Berkeley, CA
| | - Erica T. Wang
- Cedars Sinai Medical Center, Obstetrics and Gynecology, Los Angeles, CA
| | - Marcelle I. Cedars
- UCSF Medical Center at Mount Zion, Center for Reproductive Health, San Francisco, CA
| | - Lee-may Chen
- UCSF Helen Diller Family Comprehensive Cancer Center, Department of Obstetrics, Gynecology and Reproductive Services, San Francisco, CA
| | - Barbara A. Cohn
- Child Health and Development Studies of the Public Health Institute, Berkeley, CA
| |
Collapse
|
26
|
Yung MMH, Ngan HYS, Chan DW. Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges. Acta Biochim Biophys Sin (Shanghai) 2016; 48:301-17. [PMID: 26764240 PMCID: PMC4886241 DOI: 10.1093/abbs/gmv128] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 10/29/2015] [Indexed: 12/25/2022] Open
Abstract
The development and strategic application of effective anticancer therapies have turned out to be one of the most critical approaches of managing human cancers. Nevertheless, drug resistance is the major obstacle for clinical management of these diseases especially ovarian cancer. In the past years, substantial studies have been carried out with the aim of exploring alternative therapeutic approaches to enhance efficacy of current chemotherapeutic regimes and reduce the side effects caused in order to produce significant advantages in overall survival and to improve patients' quality of life. Targeting cancer cell metabolism by the application of AMP-activated protein kinase (AMPK)-activating agents is believed to be one of the most plausible attempts. AMPK activators such as 5-aminoimidazole-4-carboxamide 1-β-d-ribofuranoside, A23187, metformin, and bitter melon extract not only prevent cancer progression and metastasis but can also be applied as a supplement to enhance the efficacy of cisplatin-based chemotherapy in human cancers such as ovarian cancer. However, because of the undesirable outcomes along with the frequent toxic side effects of most pharmaceutical AMPK activators that have been utilized in clinical trials, attentions of current studies have been aimed at the identification of replaceable reagents from nutraceuticals or traditional medicines. However, the underlying molecular mechanisms of many nutraceuticals in anticancer still remain obscure. Therefore, better understanding of the functional characterization and regulatory mechanism of natural AMPK activators would help pharmaceutical development in opening an area to intervene ovarian cancer and other human cancers.
Collapse
Affiliation(s)
- Mingo M H Yung
- Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | - Hextan Y S Ngan
- Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | - David W Chan
- Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| |
Collapse
|
27
|
Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI. Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Res 2016; 76:796-804. [PMID: 26685161 PMCID: PMC4762194 DOI: 10.1158/0008-5472.can-15-2298] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Accepted: 12/01/2015] [Indexed: 11/16/2022]
Abstract
Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced stages of the disease. Therefore, the identification of robust biomarkers of early disease is a clinical priority. Metabolomic profiling is an emerging diagnostic tool enabling the detection of biomarkers reflecting alterations in tumor metabolism, a hallmark of cancer. In this study, we performed metabolomic profiling of serum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients with benign or non-neoplastic lesions. We report metabolites of hydroxybutyric acid (HBA) as novel diagnostic and prognostic biomarkers associated with tumor burden and patient survival. The accumulation of HBA metabolites caused by HGSOC was also associated with reduced expression of succinic semialdehyde dehydrogenase (encoded by ALDH5A1), and with the presence of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alterations in cancer cell migration and invasion. In conclusion, our findings represent the first comprehensive metabolomics analysis in HGSOC and propose a new set of metabolites as biomarkers of disease with diagnostic and prognostic capabilities.
Collapse
Affiliation(s)
- Mika Hilvo
- VTT Technical Research Centre of Finland, P.O. Box 1000, FI-02044 VTT, Espoo, Finland
| | - Ines de Santiago
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
| | | | | | - Jan Budczies
- Institute of Pathology, Charité University Hospital, 10117 Berlin, Germany
| | - Marc Kuhberg
- Department for Gynecology, Campus Virchow Clinic, Charité Medical University, Berlin
| | - Manfred Dietel
- Institute of Pathology, Charité University Hospital, 10117 Berlin, Germany
| | - Tero Aittokallio
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Florian Markowetz
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
| | - Carsten Denkert
- Institute of Pathology, Charité University Hospital, 10117 Berlin, Germany
| | - Jalid Sehouli
- Department for Gynecology, Campus Virchow Clinic, Charité Medical University, Berlin
- On behalf of the Tumor Bank Ovarian Cancer Network (www.toc-network.de)
| | - Christian Frezza
- MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK
| | | | - Elena Ioana Braicu
- Department for Gynecology, Campus Virchow Clinic, Charité Medical University, Berlin
- On behalf of the Tumor Bank Ovarian Cancer Network (www.toc-network.de)
| |
Collapse
|
28
|
Kulshrestha A, Katara GK, Ibrahim S, Pamarthy S, Jaiswal MK, Gilman Sachs A, Beaman KD. Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget 2016; 6:3797-810. [PMID: 25686833 PMCID: PMC4414154 DOI: 10.18632/oncotarget.2902] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Accepted: 12/14/2014] [Indexed: 01/25/2023] Open
Abstract
Tumor associated vacuolar H+-ATPases (V-ATPases) are multi-subunit proton pumps that acidify tumor microenvironment, thereby promoting tumor invasion. Subunit ‘a’ of its V0 domain is the major pH sensing unit that additionally controls sub-cellular targeting of V-ATPase and exists in four different isoforms. Our study reports an elevated expression of the V-ATPase-V0a2 isoform in ovarian cancer(OVCA) tissues and cell lines(A2780, SKOV-3 and TOV-112D). Among all V0’a’ isoforms, V0a2 exhibited abundant expression on OVCA cell surface while normal ovarian epithelia did not. Sub-cellular distribution of V-ATPase-V0a2 confirmed its localization on plasma-membrane, where it was also co-associated with cortactin, an F-actin stabilizing protein at leading edges of cancer cells. Additionally, V0a2 was also localized in early and late endosomal compartments that are sites for modulations of several signaling pathways in cancer. Targeted inhibition of V-ATPase-V0a2 suppressed matrix metalloproteinase activity(MMP-9 & MMP-2) in OVCA cells. In conclusion, V-ATPase-V0a2 isoform is abundantly expressed on ovarian tumor cell surface in association with invasion assembly related proteins and plays critical role in tumor invasion by modulating the activity of matrix-degrading proteases. This study highlights for the first time, the importance of V-ATPase-V0a2 isoform as a distinct biomarker and possible therapeutic target for treatment of ovarian carcinoma.
Collapse
Affiliation(s)
- Arpita Kulshrestha
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Gajendra K Katara
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Safaa Ibrahim
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.,Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Egypt
| | - Sahithi Pamarthy
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Mukesh K Jaiswal
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Alice Gilman Sachs
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Kenneth D Beaman
- Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| |
Collapse
|
29
|
Gaul DA, Mezencev R, Long TQ, Jones CM, Benigno BB, Gray A, Fernández FM, McDonald JF. Highly-accurate metabolomic detection of early-stage ovarian cancer. Sci Rep 2015; 5:16351. [PMID: 26573008 PMCID: PMC4647115 DOI: 10.1038/srep16351] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 10/13/2015] [Indexed: 01/17/2023] Open
Abstract
High performance mass spectrometry was employed to interrogate the serum metabolome of early-stage ovarian cancer (OC) patients and age-matched control women. The resulting spectral features were used to establish a linear support vector machine (SVM) model of sixteen diagnostic metabolites that are able to identify early-stage OC with 100% accuracy in our patient cohort. The results provide evidence for the importance of lipid and fatty acid metabolism in OC and serve as the foundation of a clinically significant diagnostic test.
Collapse
Affiliation(s)
- David A Gaul
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta GA 30332 (USA).,School of Biology, Integrated Cancer Research Center, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | - Roman Mezencev
- School of Biology, Integrated Cancer Research Center, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | - Tran Q Long
- College of Computing, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | - Christina M Jones
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | | | - Alexander Gray
- College of Computing, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | - Facundo M Fernández
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta GA 30332 (USA).,Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| | - John F McDonald
- School of Biology, Integrated Cancer Research Center, Georgia Institute of Technology, Atlanta GA 30332 (USA).,Ovarian Cancer Institute, Atlanta GA 30342 (USA).,Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta GA 30332 (USA)
| |
Collapse
|
30
|
Wang G, Li X, Tian W, Wang Y, Wu D, Sun Z, Zhao E. Promoter DNA methylation is associated withKLF11expression in epithelial ovarian cancer. Genes Chromosomes Cancer 2015; 54:453-62. [PMID: 25931269 DOI: 10.1002/gcc.22257] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 03/09/2015] [Indexed: 01/19/2023] Open
Affiliation(s)
- Guan Wang
- Department of Obstetrics and Gynecology; Tianjin Central Hospital of Obstetrics and Gynecology; Tianjin 300100 China
| | - Xianfeng Li
- State Key Laboratory of Medical Genetics; Central South University; Changsha Hunan 410078 China
| | - Weiping Tian
- Tianjin Research Center of Basic Medical Science; Tianjin Medical University; Tianjin 300070 China
| | - Yan Wang
- Institute of Psychology, Chinese Academy of Sciences; Beijing 100101 China
| | - Dandan Wu
- Department of Obstetrics and Gynecology; Tianjin Central Hospital of Obstetrics and Gynecology; Tianjin 300100 China
| | - Zhongsheng Sun
- Beijing Institute of Life Science, Chinese Academy of Science; Beijing 100101 China
| | - Enfeng Zhao
- Department of Obstetrics and Gynecology; Chinese PLA General Hospital; Beijing 100853 China
| |
Collapse
|
31
|
Woolery KT, Hoffman MS, Kraft J, Nicosia SV, Kumar A, Kruk PA. Urinary interleukin-1β levels among gynecological patients. J Ovarian Res 2014; 7:104. [PMID: 25403235 PMCID: PMC4247195 DOI: 10.1186/s13048-014-0104-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 10/26/2014] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new strategies for OC detection. Since the deregulation of inflammatory mediators can contribute to OC development, the purpose of this pilot study was to determine whether elevated urinary levels of Interleukin-1beta (IL-1 beta) are associated with OC and associated clinical parameters. METHODS Urinary and serum levels of IL-1 beta were analyzed by ELISA from a patient cohort consisting of healthy women (N = 10), women with ovarian benign disease (N = 23), women with OC (N = 32), women with other benign gynecological conditions (N = 22), and women with other gynecological cancers (N = 6). RESULTS Average urinary IL-1 beta levels tended to be elevated in ovarian benign (1.26 pg/ml) and OC (1.57 pg/ml) patient samples compared to healthy individuals (0.36 pg/ml). Among patients with benign disease, urinary IL-1β levels were statistically higher in patients with benign inflammatory gynecologic disease compared to patients with non-inflammatory benign disease. Interestingly, urinary IL-1 beta levels tended to be 3-6x greater in patients with benign ovarian disease or OC as well as with a concomitant family history of ovarian and/or breast cancer compared to similar patients without a family history of ovarian and/or breast cancer. Lastly, there was a pattern of increased urinary IL-1 beta with increasing body mass index (BMI); patients with a normal BMI averaged urinary IL-1 beta levels of 0.92 pg/ml, overweight BMI averaged urinary IL-1 beta levels of 1.72 pg/ml, and obese BMI averaged urinary IL-1 beta levels of 5.26 pg/ml. CONCLUSIONS This pilot study revealed that urinary levels of IL-1 beta are elevated in patients with epithelial OC supporting the thought that inflammation might be associated with cancer progression. Consequently, further studies of urinary IL-1 beta and the identification of an inflammatory profile specific to OC development may be beneficial to reduce the mortality associated with this disease.
Collapse
Affiliation(s)
- Kamisha T Woolery
- Department of Pathology and Cell Biology, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL, 33612, USA.
| | - Mitchel S Hoffman
- Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, 33612, USA.
| | - Joshua Kraft
- Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, 33612, USA.
| | - Santo V Nicosia
- Department of Pathology and Cell Biology, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL, 33612, USA.
| | - Ambuj Kumar
- Department of Internal Medicine, University of South Florida, Tampa, FL, 33612, USA.
| | - Patricia A Kruk
- Department of Pathology and Cell Biology, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL, 33612, USA. .,Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, 33612, USA. .,H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.
| |
Collapse
|
32
|
Amal H, Shi DY, Ionescu R, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Haick H. Assessment of ovarian cancer conditions from exhaled breath. Int J Cancer 2014; 136:E614-22. [PMID: 25159530 DOI: 10.1002/ijc.29166] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Revised: 08/19/2014] [Accepted: 08/21/2014] [Indexed: 01/14/2023]
Abstract
We present a pilot study that aims to examine the possibility to easily and noninvasively detect and discriminate females with ovarian cancer (OC) from females that have no tumor(s) and from females that have benign genital tract neoplasia, using exhaled breath samples. The study is based on clinical samples and data from 182 females, as follows: 48 females with OC, 48 tumor-free controls and 86 females with benign gynecological neoplasia. Analysis of the breath samples with gas chromatography linked with mass spectrometry shows that decanal, nonanal, styrene, 2-butanone and hexadecane could serve as potential volatile markers for OC. Analysis of the same samples with tailor-made nanoarrays shows good discrimination between females with OC and females that have either no tumor or benign genital tract neoplasia (71% for accuracy, sensitivity and specificity). Conversely, the nanoarray output shows excellent discrimination between the OC patients and the tumor-free controls (79% sensitivity, 100% specificity and 89% accuracy). These results suggest that the nanoarray approach might be useful to avoid unnecessary complicated or expensive tests for tumor-free females in case of a negative result. In the case of positive result, the test will indicate with high probability the presence of OC.
Collapse
Affiliation(s)
- Haitham Amal
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Jerman KG, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol 2014; 12:278. [PMID: 25185697 PMCID: PMC4167500 DOI: 10.1186/1477-7819-12-278] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Accepted: 08/16/2014] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Determination of the tumor marker concentration in peritoneal fluid (PF) may help to assess its potential to detect small concentration changes between benign ovarian pathology and early stage ovarian cancer. Peritoneal washing, which can also be obtained when PF is absent, is already included in the International Federation of Gynecology and Obstetrics (FIGO) staging classification for ovarian cancer but sampling has not yet been standardized. Since our aim was to evaluate the relationship between marker concentration in PF and washing, standardization of the sampling protocol was a prerequisite to ensure reliable results. METHODS Thirty-three women with non-malignant pathology of the reproductive organs were included in the study. We used three promising tumor markers for evaluation of the marker concentration in local fluid: osteopontin (sOPN), splice variant 6 of sCD44 (sCD44-v6) and vascular cell adhesion molecule-1 (sVCAM-1). After aspiration of PF, washing of the uterus, ovaries and pelvic peritoneum was performed with saline solution. Patients were divided into two groups based on the solution volume: A-20 ml and B-50 ml. To determine the efficiency of washing in relation to solution volume, washing was repeated three times. Concentrations of markers in samples were determined using flow cytometry. RESULTS Mean concentrations of markers were significantly higher (P <0.001) in PF than in the first washing. We demonstrated a significant positive correlation between marker concentrations in PF and first washing (sOPN: r = 0.447, P = 0.048; sCD44-v6: r = 0.660, P = 0.002; sVCAM-1: r = 0.526, P = 0.017). When using a smaller solution volume for washing, significantly higher (sVCAM-1: 2.5-fold, P = 0.021; sOPN: 3-fold, P = 0.024) or equal (sCD44-v6) mean concentrations of tumor markers were obtained. CONCLUSIONS Our work demonstrates for the first time that concentrations of sOPN, sCD44-v6 and sVCAM-1 in PF correlate with peritoneal washing in women with non-malignant pathology of the reproductive organs. This indicates that, for selected tumor markers, washing can replace PF when PF is absent. A standardized protocol for sampling PF and performing washing during laparoscopy was established.
Collapse
Affiliation(s)
- Katarina Galic Jerman
- />Department of Gynecology, Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
- />Department of Gynecology and Obstetrics, Faculty of Medicine, University Ljubljana, Slajmarjeva 3, 1000 Ljubljana, Slovenia
| | - Borut Kobal
- />Department of Gynecology, Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
- />Department of Gynecology and Obstetrics, Faculty of Medicine, University Ljubljana, Slajmarjeva 3, 1000 Ljubljana, Slovenia
| | - Marina Jakimovska
- />Department of Gynecology, Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
- />Department of Gynecology and Obstetrics, Faculty of Medicine, University Ljubljana, Slajmarjeva 3, 1000 Ljubljana, Slovenia
| | - Ivan Verdenik
- />Department of Gynecology, Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
- />Department of Gynecology and Obstetrics, Faculty of Medicine, University Ljubljana, Slajmarjeva 3, 1000 Ljubljana, Slovenia
| | - Katarina Cerne
- />Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia
| |
Collapse
|
34
|
Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites. Radiol Oncol 2014; 48:307-13. [PMID: 25177246 PMCID: PMC4110088 DOI: 10.2478/raon-2013-0066] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 08/30/2013] [Indexed: 11/20/2022] Open
Abstract
Background Vascular cell adhesion molecule-1 (VCAM-1) is associated with ovarian cancer progression but the origin of its soluble form (sVCAM-1) in serum is not well investigated. The purpose of this study was to elucidate whether the concentration of sVCAM-1 in serum correlates with the concentration in ascites, that represents local tumour environment, and with systemic inflammation, various clinicopathological characteristics, and patient outcome. Patients and methods. Thirty-six patients with advanced ovarian cancer were included in the study. Serum for sVCAM-1 analysis was obtained prior to surgery. Ascites samples were collected at the beginning of the operation. Clinical data were collected from patients’ medical records. sVCAM-1 in samples was analysed by flow cytometric bead-based assay. The mean follow-up period was 11 months (range 0–23) from the time of surgery. Results Serum sVCAM-1 concentrations are positively correlated to ascites sVCAM-1 concentrations. There was a weakly positive correlation of serum sVCAM-1 with tumour size and no correlation with inflammatory tumour markers, FIGO stage or grade. Higher concentrations of sVCAM-1 were associated with poor disease outcome (death from ovarian cancer) in almost all cases before chemotherapy was started. Conclusions This is the first study demonstrating that serum concentrations of sVCAM-1 in advanced ovarian cancer patients correlate with sVCAM-1 concentrations in ascites, thus expressing the biologic potential of malignant disease to metastasis, rather than systemic inflammation. Higher serum and ascites sVCAM-1 concentrations might have predictive potential for different biologic behaviour.
Collapse
|
35
|
Song L, Ma N, Han L, Yan H, Yan B, Yuan Z, Cao B. Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing. Hum Immunol 2014; 75:239-44. [DOI: 10.1016/j.humimm.2013.12.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 10/08/2013] [Accepted: 12/17/2013] [Indexed: 01/11/2023]
|
36
|
Garibay-Cerdenares OL, Hernández-Ramírez VI, Osorio-Trujillo JC, Hernández-Ortíz M, Gallardo-Rincón D, Cantú de León D, Encarnación-Guevara S, Villegas-Pineda JC, Talamás-Rohana P. Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients. J Ovarian Res 2014; 7:27. [PMID: 24576319 PMCID: PMC3943579 DOI: 10.1186/1757-2215-7-27] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 02/19/2014] [Indexed: 12/18/2022] Open
Abstract
Background Ovarian cancer is the most lethal gynecologic disease due to delayed diagnosis, and ascites production is a characteristic of patients in advanced stages. The aim of this study was to perform the proteomic analysis of ascitic fluids of Mexican patients with ovarian carcinoma, in order to detect proteins with a differential expression pattern in the continuing search to identify biomarkers for this disease. Methods Samples were collected from 50 patients from the Instituto Nacional de Cancerología of México under informed consent and with approval of the bioethics and scientific committees. After elimination of abundant proteins (Albumin/IgGs) samples were processed for 2D electrophoresis and further protein identification by Mass Spectrometry (MALDI-TOF). Molecules of interest were followed by western blot and lectin binding assays, and their tissue location by histo-immunofluorescence and confocal analysis. Results and discussion An area with a differential expression pattern among samples was located in the 2D gels. Identified proteins were 6 alpha 1 isoforms and 1 alpha 2 isoform of Haptoglobin, and 2 isoforms of Transthyretin. While Transthyretin isoforms were constitutively expressed in all samples, clear differences in the expression pattern of Haptoglobin alpha isoforms were found. Moreover, increased levels of fucosylation of Haptoglobin alpha isoforms analyzed in 40 samples by Aleuria aurantia lectin binding by 1D overlay assay showed a positive correlation with advanced stages of the disease. Tissue detection of Haptoglobin and its fucosylated form, by histo-immunofluorescence in biopsies of ovarian cancer, also showed a correlation with ovarian cancer progression. Moreover, results show that fucosylated Haptoglobin is produced by tumor cells. Conclusions Increased numbers of highly fucosylated Haptoglobin alpha isoforms in ascitic fluids and the presence of fucosylated Haptoglobin in tumor tissues of ovarian cancer Mexican patients associated with advanced stages of the disease, reinforce the potential of fucosylated Haptoglobin alpha isoforms to be characterized as biomarkers for disease progression.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Patricia Talamás-Rohana
- Departamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av, Instituto Politécnico Nacional 2508, Col, San Pedro Zacatenco, Delegación Gustavo A, Madero, México, D,F, 07360, México.
| |
Collapse
|
37
|
Al-Ogaidi I, Gou H, Aguilar ZP, Guo S, Melconian AK, Al-kazaz AKA, Meng F, Wu N. Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots. Chem Commun (Camb) 2014; 50:1344-6. [PMID: 24345782 DOI: 10.1039/c3cc47701k] [Citation(s) in RCA: 127] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
A cancer biomarker immuno-sensor has been developed by utilizing the chemiluminescence resonance energy transfer to graphene quantum dots.
Collapse
Affiliation(s)
- Israa Al-Ogaidi
- Department of Biotechnology
- College of Science
- University of Baghdad
- Baghdad, Iraq
- Department of Mechanical and Aerospace Engineering
| | - Honglei Gou
- Department of Mechanical and Aerospace Engineering
- West Virginia University
- Morgantown, USA
| | | | - Shouwu Guo
- Key Laboratory for Thin Film and Microfabrication of the Ministry of Education
- Research Institute of Micro/Nano Science and Technology
- Shanghai Jiao Tong University
- Shanghai 200240, China
| | - Alice K. Melconian
- Department of Biotechnology
- College of Science
- University of Baghdad
- Baghdad, Iraq
| | | | - Fanke Meng
- Department of Mechanical and Aerospace Engineering
- West Virginia University
- Morgantown, USA
| | - Nianqiang Wu
- Department of Mechanical and Aerospace Engineering
- West Virginia University
- Morgantown, USA
| |
Collapse
|
38
|
Leung F, Diamandis EP, Kulasingam V. Ovarian Cancer Biomarkers. Adv Clin Chem 2014. [DOI: 10.1016/b978-0-12-801401-1.00002-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Diaconu I, Cristea C, Hârceagă V, Marrazza G, Berindan-Neagoe I, Săndulescu R. Electrochemical immunosensors in breast and ovarian cancer. Clin Chim Acta 2013; 425:128-38. [DOI: 10.1016/j.cca.2013.07.017] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 07/19/2013] [Accepted: 07/20/2013] [Indexed: 12/20/2022]
|
40
|
Horvath G, Andersson H, Nemes S. Cancer odor in the blood of ovarian cancer patients: a retrospective study of detection by dogs during treatment, 3 and 6 months afterward. BMC Cancer 2013; 13:396. [PMID: 23978091 PMCID: PMC3765942 DOI: 10.1186/1471-2407-13-396] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Accepted: 08/22/2013] [Indexed: 11/10/2022] Open
Abstract
Background In recent decades it has been noted that trained dogs can detect specific odor molecules emitted by cancer cells. We have shown that the same odor can also be detected in the patient’s blood with high sensitivity and specificity by trained dogs. In the present study, we examined how the ability of dogs to detect this smell was affected by treatment to reduce tumor burden, including surgery and five courses of chemotherapy. Methods In Series I, one drop of plasma from each of 42 ovarian cancer patients (taken between the fifth and sixth courses of chemotherapy) and 210 samples from healthy controls were examined by two trained dogs. All 42 patients in Series I had clinical complete responses, all except two had normal CA-125 values and all were declared healthy after primary treatment. In Series II, the dogs examined blood taken from a new subset of 10 patients at 3 and 6 months after the last (sixth) course of chemotherapy. Results In Series I, the dogs showed high sensitivity (97%) and specificity (99%), for detecting viable cancer cells or molecular cancer markers in the patients’ plasma. Indeed, 29 of 42 patients died within 5 years. In Series II, the dogs indicated positive samples from three of the 10 patients at both the 3- and 6-month follow-up. All three patients had recurrences, and two died 3–4 years after the end of treatment. This was one of the most important findings of this study. Seven patients were still alive in January 2013. Conclusions Although our study was based on a limited number of selected patients, it clearly suggests that canine detection gave us a very good assessment of the prognosis of the study patients. Being able to detect a marker based on the specific cancer odor in the blood would enhance primary diagnosis and enable earlier relapse diagnosis, consequently increasing survival.
Collapse
Affiliation(s)
- György Horvath
- Institute of Clinical Sciences, Department of Oncology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg SE-41345, Sweden.
| | | | | |
Collapse
|